H.C. Wainwright lowered the firm’s price target on ALX Oncology (ALXO) to $5 from $25 and keeps a Buy rating on the shares after the company reported final data from the Phase 2 ASPEN-06 study. The firm is encouraged by the data but lowered ALX’s peak penetration rate estimate in head and neck cancer to 10% from 25% given the evolving competitive landscape.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALXO: